RSA Viewpoints
New talent needed for a new era of market access in the medtech industry
The last decade has seen the unprecedented growth of innovative and improved medical technologies. In turn, this has led to the development of a...
RSA Talent Equity® | 2nd Annual Successful Biotech Boards
This is the second of our annual Talent Equity® reports analysing the performance of biotech Boards, CEOs and Chairs in Europe and the USA....
Pharmaceutical Market Europe | Adding value to company leadership
For a forward-looking industry, the life science sector is remarkably conservative, rarely looking outside for talent and often trying to home-grow its skills. In...
RSA Viewpoint | Life Sciences leadership in flux
Leadership and talent agendas in the life sciences are adapting to major external influences on the life sciences sector – economic, political, technological and...
The UK is a leader in life sciences. How can we make sure that it remains No.1 in Europe?
After spending a day in mid-October at this year’s excellent UK BioScience Forum, I was left with one particular thought ringing loud and clear...
How hiring the best leaders maximizes biotech exit values
We’ve seen some major exits in the biotech market in 2017. Early in the year, in Switzerland alone, Actelion was sold to Johnson &...
Recruitment International | The key to success in life sciences
Alex Bennett, CEO of The RSA Group, discusses the current opportunities and leadership challenges in the life sciences sector – and how to succeed...
RSA Viewpoint | The Successful Leader
There’s no doubt the leader’s job is becoming increasingly difficult in today’s environment. We’re experiencing unprecedented levels of change – societal, political, economic and...
Engaging with executive interims – time for a fresh perspective
Habits are hard to break and all too often we return to established patterns of behaviour rather than looking for innovative ways to do...
Diversity: A call to arms for Biotech Leaders and Investors
A panel discussion, led by The RSA Group, at the recent BIA UK CEO & Investor Forum discussed the demographic time bomb facing biotech boards...
The value of engaging Pharmacoeconomic executive interims
So what is Pharmacoeconomics? Pharmacoeconomics, is the “scientific discipline which evaluates the clinical, economic and humanistic aspects of pharmaceutical products, services, and programmes, as...
Pharmaceutical Market Europe | Massive Uncertainty is the new norm
There’s a lot of change coming: changes of practice, thinking and behaviour, all of which represent challenge and opportunity. Those leaders who recognise it...
Hiring international executives and the (true) costs of failure
A tale of two …points of view? “It was the best of times, it was the worst of times, it was the age of...
Building talent and saving lives
London was the setting last week for the 25th Annual Meeting of the International Society for Cellular Therapy. The huge increase of clinical trials...
RSA Talent Equity® | Biotech IPOs and Deals 2016
In our latest Talent Equity® Report, we examine the performance of biotech leaders whose companies IPO’d or were active in deal-making in 2016. Leaders...